The usual model of drug development is
Spot opportunity > spend lots on R&D > Go into production > maximise sales > recoup money as soon as possible > Profit!
However, with new antibiotics we, as society absolutely do not want them to maximise sales. Ideally we don't want any production at all. At worst, we'd like it to be used in a handful of cases for 5, 10 or 20 years, keeping it as a treatment of last resource.
In such circumstances you can see the problem for the pharmaceuticals. Personally, I think there needs to be some kind of prize fund that can let the companies recoup (and make a decent profit) from antibiotic discoveries. Either that or public-sector research.